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Dear Editor,
The median patients’ age at diagnosis of non-small-
cell lung carcinoma (NSCLC), is 65 years. The majority 
of advanced NSCLC patients require molecular diagnosis 
of tumor tissue for qualification to molecularly targeted 
therapies [tyrosine kinase inhibitors of epidermal growth 
factor receptor (EGFR), ALK or ROS1]. The molecular 
background of NSCLC in different age groups (especially 
in the youngest and the oldest groups) is poorly studied. 
Recent data have suggested that EGFR mutations are as-
sociated with an older age at diagnosis (adenocarcinoma 
female patients of Asian origin) [1]. However, in small 
retrospective studies, a higher incidence of EGFR muta-
tions in young patients has also been suggested [2-4]. 
More recent studies have suggested that age may not be 
as significant predictor of EGFR mutations status [4-6].
In this commentary, we will attempt to prove that 
EGFR mutation status in NSCLC is highly dependent on 
the patients’ age. Our study enrolled the largest group of 
homogenous Caucasian NSCLC patients tested for EGFR 
mutations.
The studied group consisted of 12651 NSCLC pa-
tients (median age: 66 ± 7.5 years, range: 25-92 years) and 
included 94.3% of adenocarcinoma, 5.3% of not otherwise 
specified NSCLC, 0.3% of large cell carcinoma, <0.1% 
of adenosquamous carcinoma and <0.1% of squamous 
cell carcinoma patients. Patients were divided into 11 age 
groups (every 5 years). Routine diagnostics of EGFR status 
was performed with molecular probes for a real-time poly-
merase chain reaction (PCR) technique on a Cobas z480 
(Roche Diagnostics AG, Basel, Switzerland) instrument.
The EGFR gene mutations were detected in 1109 
patients (8.77%), including 573 exon 19 deletions (4.53%), 
358 L858R substitutions (2.83%) and 178 rare or double 
mutations (1.41%). The EGFR gene mutations occurred 
significantly more frequently in female than in male pa-
tients (14.4 vs. 4.8%; χ2 = 352.5, p <0.00001). In young 
patients (25 to <50 years old), the incidence of mutations 
was significantly higher (17.26 vs. 8.39%; χ2 = 50.21, 
p <0.00001) than in older patients (>50 years old). The 
incidence of mutations was 23.4% in young women and 
13.9% in older women (χ2 = 19.24, p = 0.000012) and 
10.6% in young men and 4.6% in older men (χ2 = 19.29, p 
= 0.000011). The differences in EGFR mutation prevalence 
in different age groups were caused by the differences in 
the frequency of the exon 19 deletion in female (χ2 = 17.46, 
p = 0.000029) and male (χ2 = 29.6, p <0.00001) patients. 
The frequency of the L858R substitution and rare or double 
mutations was similar in the studied age groups in both 
genders. Deletion in exon 19 was the dominant mutation in 
young men (deletion frequency 74.1%, L858R frequency 
7.4%, rare or double mutations frequency 18.5% of all 
examined EGFR mutations). In older men and in young 
and older women, exon 19 deletion frequency was 51.8, 
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56.9 and 50.2%, respectively, whereas the incidence of the 
L859R substitution was 30.6, 23.1 and 34.9%, respectively. 
The incidence of the exon 19 deletion gradually decreased 
along with increasing age of male patients. In women, 
the prevalence of the exon 19 deletion was highest in the 
youngest and the oldest age groups. Thus, clear trends 
were not observed for the L858R substitution and rare or 
double mutations (Figure 1).
Our results indicate the entity of hereditary molecular 
background for development of the exon 19 deletion in 
EGFR in young adults [our preliminary next-generation 
sequencing (NGS)] results indicate mutations in tumor 
suppressor genes, e.g., MSH2). However, smoking behav-
ior may influence the presence of EGFR gene mutations 
in different female age groups. Moreover, diagnostics of 
EGFR mutations in young and older patients should be 
particularly careful and meticulous (correct sequence of 
genetic testing).
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Figure 1. The prevalence of exon 19 deletions of EGFR gene in 
different age groups of patients with NSCLC.
